37th Annual Meeting Society for Immunotherapy of Cancer (SITC) 2022 – Abstracts

Who We Are
Clinical Trials & Patients
Science
Investors
News
Join Us
Contact Us

37th Annual Meeting Society for Immunotherapy of Cancer (SITC) 2022 – Abstracts

Nov 11, 2022

Abstract Number 1103

Half-life extended, conditionally active IFNa prodrug induces tumor-selective activation and potent antitumor response

Abstract Number 1191

STRO-003 is a novel ROR1-targeted ADC for breast and lung cancer

Abstract Number 1359

Half-life extended engineered IL18 variants that escape the negative regulation of IL18BP

Dedicated to our patients
and changing the future of oncology

SITE MAP | PRIVACY POLICY | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.